Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks
NCT01068600 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 318
Last updated 2011-08-19
Summary
This 12-week study evaluated the efficacy and safety of indacaterol versus placebo.
Conditions
Interventions
- DRUG
-
Indacaterol
Once daily via single-dose dry powder inhaler (SDDPI)
- DRUG
-
Placebo to indacaterol
Once daily via SDDPI
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-01-31
- Primary Completion
- 2010-06-30
Countries
- United States
Study Locations
More Related Trials
-
Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT01543828 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00677807 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations
NCT02418468 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control
NCT00393458 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Indacaterol 150 µg Versus Formoterol
NCT01377428 ·Status: WITHDRAWN ·Phase: PHASE4
-
Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00615030 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01604278 ·Status: COMPLETED ·Phase: PHASE3
-
26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00463567 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00669617 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control
NCT00567996 ·Status: COMPLETED ·Phase: PHASE3
-
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00622635 ·Status: COMPLETED ·Phase: PHASE3
-
Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00794157 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)
NCT00821093 ·Status: COMPLETED ·Phase: PHASE3
-
A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
NCT01712516 ·Status: COMPLETED ·Phase: PHASE3
-
Cardiac Safety of Indacaterol
NCT01263808 ·Status: COMPLETED ·Phase: PHASE1
-
Indacaterol EfectIveness In COPD Patients With Tuberculosis History
NCT01778062 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control
NCT01715311 ·Status: WITHDRAWN ·Phase: PHASE4
-
An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)
NCT00636961 ·Status: COMPLETED ·Phase: PHASE2
-
Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00403845 ·Status: COMPLETED ·Phase: PHASE2
-
Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)
NCT00396604 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma
NCT00403637 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
NCT00846586 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients
NCT01727024 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)
NCT00665600 ·Status: COMPLETED ·Phase: PHASE3
-
Simvastatin in Chronic Obstructive Pulmonary Disease (COPD)
NCT00680641 ·Status: UNKNOWN ·Phase: PHASE4